Giving Us a Shot Against Cancer: The Real Promise of mRNA Vaccines

With a measles outbreak rolling across my home state of Pennsylvania, vaccines are in the news yet again. Most people first heard the term "mRNA" during the pandemic, when the technology powered the fastest vaccine rollout in history. What fewer people realize is that fighting viruses was never the only ambition for this technology. For decades, the dream behind mRNA was to take on a far bigger target: cancer. And this month, that dream took its most convincing step yet toward reality.

In August, Moderna and Merck announced that a personalized mRNA cancer vaccine had succeeded in a large, late-stage clinical trial, the first time this approach has cleared that bar. For a field that has spent years promising more than it could prove, it was a genuine milestone. It's worth understanding what actually happened, why scientists are excited, and what it does and doesn't mean for investors.

What an mRNA cancer vaccine actually is

Let’s start with the word "vaccine," because it's a little misleading here. You don't take this shot to avoid getting cancer the way you take a flu shot to avoid the flu. Instead, it's given to people who have already had a tumor removed, to stop the cancer from coming back.

Here's the elegant part. Every person's tumor carries its own unique set of mutations, little molecular flags that mark a cell as cancerous. These vaccines are custom-built for each patient: doctors sequence the individual's tumor, identify up to a few dozen of those unique flags, and then use mRNA (essentially a set of biological instructions) to teach the patient's own immune system to recognize and hunt down any cancer cell carrying them. It's less like a traditional vaccine and more like handing the immune system a personalized wanted poster to help it identify the cancer cells.

This is why the technology is such a big deal beyond any single disease. The same platform can, in theory, potentially make a tailored treatment for almost any tumor.

The breakthrough, in plain terms

The trial that made news studied melanoma, the deadliest skin cancer. More than 1,100 patients who'd had their tumors surgically removed received either the personalized vaccine (called intismeran) combined with the established immunotherapy drug Keytruda, or Keytruda alone. The group that received the vaccine saw their cancer return or spread significantly less often.

That built on earlier results showing the combination cut the risk of recurrence or death by roughly half compared with Keytruda by itself. The chief medical officer of the American Society of Clinical Oncology called the new result "a monumental leap forward." Crucially, this was the first Phase 3 trial (the large, rigorous, final stage before applying for FDA approval) to validate the approach. Years of promise finally met hard proof.

And melanoma is just the opening act. Moderna and Merck have trials underway in lung, bladder, and kidney cancers, with early-stage work in pancreatic and stomach cancers. BioNTech, the company behind the other famous COVID vaccine, is running its own trials in colon and pancreatic cancer. A wave of results is expected over the next few years.

The investment outlook

For investors, a scientific milestone and a good investment are related but very different things, and the gap between them is where caution belongs.

The market's reaction was explosive. On the news, Moderna's stock had one of the largest single-day jumps of any big company in years, adding tens of billions of dollars in value in hours. Merck climbed to a record high, and BioNTech jumped more than 20%. The excitement is understandable. Moderna in particular has been searching for a way to prove it's more than a COVID-vaccine company, and this is exactly the kind of validation it needed.

But look past the headline pop and the picture gets more complicated. Moderna is still losing a great deal of money, and its revenue has fallen sharply from its pandemic peak. Much of the optimism now baked into its stock rests on a cancer vaccine that hasn't sold a single dose yet. When a company's share price is pricing in years of future success that hasn't arrived, the room for disappointment grows.

The pure-play mRNA companies (Moderna, BioNTech) offer the most direct exposure but also the most downside. Merck, whose drug Keytruda is crucial to the winning combination, shares in the potential upside and is a more stable established business. There are also other potential investment angles, like the companies that make the gene-sequencing machines every personalized vaccine requires. Each carries a different mix of risk and reward, and if you own a broad healthcare fund or an index fund, you likely already hold several of them.

The honest caveats

Optimism is warranted here, but so is a clear head about what still stands in the way.

First, manufacturing. Building a unique vaccine for each individual patient is extraordinarily complex and, historically, expensive. Moderna says it has automated much of the process, but scaling that up to serve, say, the 100,000-plus new melanoma cases in the U.S. each year is a genuine challenge that hasn't been fully solved.

Second, and more important, melanoma may be the easy case. It's an unusually mutation-heavy cancer, which gives the immune system lots of flags to target, and it already responds relatively well to immunotherapy. Some analysts caution that the market is pricing these vaccines as if they'll work across many cancers like a blockbuster drug, when they may prove effective only in a narrower set. The tumors up next, kidney, bladder, and especially pancreatic, are far tougher targets. Success against melanoma does not guarantee success against them.

A sobering reminder of that possibility arrived this week. Even as Moderna's melanoma news was still sinking in, BioNTech announced it was terminating a mid-stage trial of its own personalized mRNA vaccine in colorectal cancer, after an independent monitoring board concluded the treatment wasn't helping patients enough to justify continuing. BioNTech's shares fell sharply on the news. It's a pointed illustration of exactly the concern above: colorectal cancer is one of those "immunotherapy-resistant" tumors with a hostile microenvironment, and the same approach that worked against melanoma simply didn't clear the bar here.

The bottom line

This is a real breakthrough, and it deserves to be recognized as one. After years of hype, an mRNA cancer vaccine has finally proven itself in a rigorous trial, and the approach could eventually change how a range of cancers are treated. That is genuinely good news, first for patients and their families, and secondarily for the companies behind these exciting developments.

For investors, the trick is to hold both truths at once: the science is exciting, but the stocks have already moved a great deal on the promise of profits that are still years away and far from guaranteed. We’ll be watching this space.

Disclosure

Convivia Financial LLC is a registered investment advisor. This article is for general informational purposes only and reflects the author's opinions as of the date of publication, which are subject to change without notice. Nothing herein constitutes investment, legal, or tax advice, nor is it a recommendation, offer, or solicitation to buy, sell, or hold any security. All investing involves risk, including loss of principal. Past performance does not guarantee future results. Information from third-party sources is believed reliable but has not been independently verified. As of the date of publication, the Firm and/or its associated persons do not hold positions in the securities discussed. Registration as an investment advisor does not imply any particular level of skill or training. For more information about the Firm, including fees and conflicts of interest, please refer to our Form ADV Part 2A available upon request.